Background/Aims: Antithrombin Ⅲ(ATⅢ) is an important endogenous anticoagulant and has strong anti-inflammatory properties. Low ATⅢ activity is considered to be a predictor of poor outcomes in several conditions, including acute kidney injury after cardiac surgery. However, the association between the ATⅢ level and the occurrence of contrast induced nephropathy (CIN) has not been elucidated. In this study, our aim was to identify the potential predictive value of ATⅢ for CIN. Methods: We enrolled a total of 460 patients who underwent coronary angiography (CAG) from January 2015 to December 2016 in coronary care units (CCU). ATⅢ activity in plasma collected before CAG was measured and <75% was considered low activity according to reference values. A cross-sectional study on CIN after CAG was conducted and the risk factors were analyzed. CIN was diagnosed according to the KDIGO guideline. Results: Of these 460 patients undergoing CAG, 125 (27.17%) progressed to CIN. The incidence of CIN was significantly higher in patients with low ATⅢ activity compared to patients with normal ATⅢ activity (Pearson's chi-squared test P=0.002). As ATⅢ activity declined, the prevalence of CIN progressively increased, with the highest value (58.8%) in patients with an ATⅢ activity <60%. Moreover, the ATⅢ activity was significantly lower in CIN patients than in non-CIN patients (84.43±16.3% vs. 92.14±13.94%, P<0.001). After multivariable analysis, ATⅢ activity <75% remained a significant independent predictor of CIN (OR 2.207,];
Introduction
Contrast-induced nephropathy (CIN) is an iatrogenic kidney injury secondary to the administration of contrast media for angiography. Despite technological advances, CIN is still ranked third in hospital acquired acute renal failure, while dehydration is ranked first followed by nephrotoxic drugs [1] . CIN incidence varies widely depending on patient conditions, concomitant risks factors, and even different diagnostic criteria. The incidence of CIN in one report was 0.6%-2.3% in the general population, while the incidence increases to 50% or more in patients with multiple risk factors [2, 3] .
Pre-existent renal insufficiency may be the most important risk factor for CIN. Diabetes mellitus, low effective circulatory volume, older age, and heart failure are also classic risk factors [2, 4, 5] . While serum creatinine (SCr) has been widely used to evaluate CIN, there are many criticisms of this marker including its loose correlation to eGFR [6] [7] [8] , its susceptibility to patient conditions (such as trauma, muscle mass, liver disease, age and immobilization) [6] as well as its failure to reflect early or slight changes in renal function [9, 10] . As a result, many clinical studies have been conducted in attempt to identify biomarkers of early CIN diagnosis. Recently, several novel renal biomarkers have been proposed to specifically predict early CIN, including neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, liver fatty acid-binding protein, kidney injury marker 1 (KIM-1), interleukin 18(IL-18) and N-Acetyl-β-(D)-Glucosaminidase (NAG) [11] [12] [13] [14] [15] [16] .
Antithrombin Ⅲ (ATⅢ), encoded by the gene SerpinC1 and produced by the liver, is a serine protease inhibitor in the coagulation cascade. ATⅢ combines with thrombin factors Ⅶa, Ⅸa, Ⅹa, and Ⅺa to exert influence on the anticoagulant process, which can be significantly accelerated by heparin-like substances [17] . In addition, ATⅢ has powerful anti-inflammatory properties, which are independent of its anticoagulant action [18, 19] . Administration of exogenous ATⅢ has been reported to exhibit protective effects against liver, lung, kidney and myocardial injury [20] [21] [22] [23] , while insufficiency of endogenous ATⅢ exacerbates renal ischemia/reperfusion injury in rats [24] .
Despite the clinical value of exogenous ATⅢ administration for some critical illnesses such as severe sepsis or disseminated intravascular coagulation (DIC) [25] [26] [27] , knowledge on the predictive value of ATⅢ activity is comparatively rare. Previously, it was reported that the initial ATⅢ level was highly predictive of patient mortality from septic shock and ATⅢ activity under 50% had the best sensitivity and specificity [28] . Additionally, low levels of postoperative ATⅢ are associated with poor outcomes in cardiac surgery and are predictive of prolonged ICU stay [29] . Our previous work confirmed that patients with low ATⅢactivity exhibit a higher risk for developing acute kidney injury (AKI) after cardiac surgery [24] . Recently, we demonstrated that exogenous ATⅢadministration in vivo attenuates CIN through inhibiting inflammation, oxidative stress, and apoptosis and through improving renal blood flow [30] . However, it is unknown whether low ATⅢ activity increases the susceptibility to CIN. The aim of this study is to investigate the association between initial ATⅢ level and the occurrence of CIN, and to evaluate the potential predictive value of ATⅢ.
Materials and Methods
We recruited a total of 460 patients who underwent coronary angiography (CAG) from January 2015 to December 2016 in coronary care units of Shanghai Jiao Tong University Affiliated Sixth People's Hospital, the First Affiliated Hospital of Harbin Medical University, Shanghai Eighth People's Hospital, and Shaoxing University Affiliated Hospital. ATⅢ activity in plasma collected before CAG was measured as reported previously [24] . According to the reference values, the normal ATⅢ activity ranged from 75 to 125%, whereas <75% was recognized as low activity.
CIN was diagnosed according to the KDIGO guideline, which was the latest criteria published in 2012. CIN was defined as any of the following: an increase in SCr by ≥0.3mg/dl (≥26.5μmol/l) within 48 hours; or an increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or urine volume <0.5ml/kg/h for 6 hours [31] . The exclusion criteria were as follows: occurrence of heart failure before or after CAG; renal toxic medicine intake; hepatic diseases; baseline eGFR <30ml/min; malignant tumors. Patients were divided into two groups according to ATⅢactivity: a normal ATⅢ group and a low ATⅢ group. For analysis of risk factors of CIN, the different cases were classified into two groups once again according to the occurrence of CIN: a CIN group and a non-CIN group. The present study was approved by the Ethics Committees of the participating institutions.
Statistical analysis SPSS (Ver 19.0, Chicago, IL) was employed to perform data analysis. Values are expressed as the mean±SD or as the number of patients (percentage). Student's t-test was used to analyze the measurement data while the Chi-Square Goodness-of-Fit test was adopted for categorical comparison. Logistic regression analysis was applied to estimate odds ratio (OR) of associated risk factors for CIN. A P value<0.05 was considered significant. For the multiple comparisons of rates, the statistical significance level was adjusted according to the Bonferroni correction.
Results

Patients with low activity of ATⅢ were predisposed to developing CIN
The study population consisted of 460 patients receiving coronary angiography with a mean age of 65.09±12.24 years, and 364 (79.1%) were men. The prevalence of CIN was 27.17% (125/460) based on the KDIGO guideline. Of the 71 cases with low ATⅢ activities, 30 (42.3%) patients developed acute kidney injury after CAG. In the group of patients with normal ATⅢ activities, there were 95(24.4%) patients suffering from CIN. The incidence of CIN was significantly higher in patients with low ATⅢ activity (Pearson's chi-squared test P=0.002). However, no differences in gender, age, preoperative proteinuria, fibrinogen degradation product(FDP), D-dimer, fibrinogen, baseline serum creatinine, blood urea nitrogen and uric acid were observed between the normal ATⅢ group and the low ATⅢ group. (Table 1) In order to further clarify the relationship between ATⅢactivity and the occurrence of CIN, we classified ATⅢ activity into four grades: <60%, 60-<75%, 75-<90%, ≥90%, and then made multiple comparisons on the CIN incidence of each grade. For the multiple comparisons of rates, the statistical significance level was adjusted according to the Bonferroni correction. Specifically, a P value <0.0083 was considered significant after adjusted:
therein, "k" referred to the number of groups(a total of 4 groups in this study), "α" referred to the statistical significance level (commonly using a P value threshold of 0.05),and "α′" referred to the adjusted statistical significance level]. As shown in Fig. 1 , the prevalence of CIN progressed as ATⅢactivity decreased. Only 19.2% patients with ATⅢ activity ≥90% developed CIN. In contrast, the incidence of CIN was the highest (58.8%) in patients with ATⅢ activity <60%. Patients with ATⅢ activity 60-<75% and 75-<90% also had significantly higher CIN incidence than patients with ATⅢ activity ≥90% (P=0.004 and P=0.001, respectively).
ATⅢ activity is an independent predictor for CIN
To analyze predisposing factors for CIN, all the patients were classified into two groups again, namely, the non-CIN group and the CIN group. A total of 125(27.17%) patients were enrolled in the CIN group with the average age of 66.58 years and a gender ratio(male/ female) of 106/19. In the group of patients without CIN, there were 335 individuals with the average age of 64.53 years and a gender ratio of 258/77. As shown in Table  2 , the activity of ATⅢ was significantly Table 1 . Incidence of contrast induced nephropathy in patients with normal or low ATⅢ activity. Abbreviations: ATⅢ, antithrombin Ⅲ; CIN, contrast induced nephropathy; FDP, fibrinogen degradation product; SCr, serum creatinine; BUN, blood urea nitrogen; UA, uric acid lower in CIN patients than that in non-CIN ones (84.43±16.3% vs. 92.14±13.94%, P<0.001). The baseline serum creatinine level was 79.3±32.18μmol/l in the CIN group, which was significantly higher than that in non-CIN group (P=0.033). Additionally, patients developing CIN had significantly lower albumin and serum sodium levels as well as significantly higher blood glucose and peak serum creatinine levels during hospitalization than those in whom CIN did not occur. However, there were no significant differences in age, gender, preoperative proteinuria, red blood cell count, hemoglobin, serum potassium, serum chlorine, diabetes mellitus, fibrinogen degradation product(FDP), D-dimer, fibrinogen, blood urea nitrogen and uric acid between two groups.
Univariate logistic regression indicated that albumin, serum sodium, blood glucose, baseline serum creatinine and ATⅢ activity <75% were all highly associated with the occurrence of CIN ( 
Discussion
This study revealed the predictive value of endogenous ATⅢ activity in the development of CIN. Patients with low ATⅢ activity were predisposed to developing CIN after coronary angiography. As a common iatrogenic acute kidney injury, CIN immensely increases medical expenses, length of stay, and hospital mortality [32] . The incidence of CIN varies widely in the literature, partly due to differences in diagnostic criteria. Although there has been no consensus on the optimal definition of CIN, the most commonly used definition provided by ESUR Contrast Media Safety Committee is a 25% relative increase or 0.5mg/dl (44μmol/l) absolute increase in serum creatinine, assessed within 3 days after the procedure [33, 34] .
However, a variety of questions and criticisms on this definition arise. It was reported that the relative definition was over-sensitive leading to false positives while the absolute definition led to false negatives [35] . Other criticisms include the absence of any functional assessment such as urinary output [7] and the short observation time, based on the evidence suggesting the peak increase of SCr could occur at 5 days rather than 3 days [31] . Recently, the KDIGO Clinical Practice Guideline redefined CIN based on changes in SCr level and on urinary output. The KDIGO definition, combining a higher relative and a lower absolute increase in SCr as well as extending the observation time up to 7 days, has been widely used in many clinical trials [36] [37] [38] .
In this study, we chose to apply the KDIGO criteria to our population. The incidence of CIN after CAG was 27.17%, which was higher than that reported in other literature [35, 37, 39] . However, it is hard to compare incidences in these studies due to distinct criteria being adopted as well as special population being enrolled. The higher prevalence in our study may be due to the fact that patients receiving coronary angiography in CCU were always concomitant with cardiovascular complications or organ dysfunction, some of which might be the risk factors for CIN, leading to patients with high risks accounting for a comparatively large proportion in our study.
ATⅢ, encoded by the gene SerpinC1 and synthesized in the liver, is not only a serine protease inhibitor in the coagulation cascade but also possesses anti-inflammatory properties [24] . Our recent study showed that patients with low ATⅢ activities presented a high risk for developing AKI after cardiac surgery and endogenous ATⅢ insufficiency exacerbated renal ischemia/reperfusion injury in rats [24] . However, administration of exogenous ATⅢ could protect from CIN through anti-inflammatory and antioxidant effects as well as improved renal blood flow [30] . In this study, we found that patients with low activity of ATⅢ had an approximately 2.2-fold greater chance of developing CIN after coronary angiography than the normal group. Meanwhile, we have revealed a predictive value of endogenous ATⅢ activity in CIN development, suggesting that it would be clinically valuable to identify patients with low ATⅢ activities before administration of contrast media.
Additionally, this study highlighted the need for monitoring kidney function more closely and taking precautions to prevent or alleviate the development of CIN in these patients. Indeed, the predictive value of ATⅢ has gradually attracted attention, despite the fact that relevant studies are comparatively limited. Previously, it was reported that a low level of initial ATⅢ was highly associated with poor outcomes in several conditions and had been identified as an important prognostic indicator [28, 40, 41] , providing new insights into the role of ATⅢ beyond its anticoagulant effects. However, the association between ATⅢ and the occurrence of CIN was unknown. To our knowledge, this is the first study that investigates the predictive value of ATⅢ in the development of CIN.
The pathophysiological mechanisms, by which low plasma ATⅢ activity correlates with CIN, are still unclear. One possible underlying mechanism may be the reduction in renal blood flow during ATⅢ deficiency. Prolonged vasoconstriction with a reduction of hemoperfusion occurs after contrast medium administration due to changes in calcium influx, increases in adenosine and endothelin, as well as impaired nitric oxide production [42] . However, a majority of individuals fail to develop CIN, partly due to other protective factors contributing to self-defense and self-repair.
ATⅢ, a natural beneficial material, can stimulate endothelial cell to release prostaglandin I 2 (PGI 2 ), which has been considered a powerful vasodilator [43] . PGI 2 is known to regulate renal cortical blood flow and protect against renal failure [24] . Therefore, low ATⅢ activity may exert adverse influence on microcirculatory haemodynamics. ATⅢ deficiency is associated with hypercoagulability, microembolism, and with increased blood viscosity, eventually aggravating renal ischemic and hypoxia injury.
Another possible mechanism may be enhanced inflammatory response during ATⅢ deficiency. In addition to its anticoagulation properties, ATⅢ exhibits powerful antiinflammatory effects in part by suppressing leukocyte recruitment, nuclear factor-κB pathways activation and cytokine production [24, 43] . Therefore, under low ATⅢ conditions, intra-renal inflammation following contrast medium administration may increase due to oxidative stress or hypoxia [44] [45] [46] [47] . However, the above explanations are speculative and the detailed molecular mechanisms involved in the adverse effects of ATⅢ deficiency on CIN should be further investigated.
The detrimental influence of low ATⅢactivity has suggested the need for supplementary therapies in patients with ATⅢ deficiency before administration of contrast medium. However, ATⅢ substitution has been previously subjected to a variety of questions and debates. It was reported that ATⅢ supplementation exhibited beneficial effects on organ function [48] , protected against development of venous thromboembolism [49] , and decreased mortality [49, 50] in patients with sepsis. Nevertheless, several meta-analyses have shown no significant beneficial effect of ATⅢ substitution on mortality in critically ill patients, whereas ATⅢ increased the risk of bleeding, especially in patients receiving concomitant heparin [51] [52] [53] .
Indeed, some points on this issue merit attention. Firstly, a majority of trials provided clinical data and made the conclusions based on a small sample size, inevitably reducing power and increasing the risk of erroneous conclusions. Therefore, much larger randomized controlled trials (RCT) of ATⅢ replacement are needed to investigate its actual efficacy and harmful effects. Secondly, we should be discreet about concomitant use of heparin. Heparin can not only overwhelmingly accelerate the anticoagulant effect of ATⅢ, but competitively prevent ATⅢ from interacting with the endothelial cellular receptors, eventually reducing ATⅢ's anti-inflammatory properties, weakening vascular protection, and increasing the risk of bleeding [51] . Thirdly, randomized controlled trials are required to verify the clinical value of ATⅢ supplementation before contrast medium administration in protecting patients with low ATⅢ activities from developing CIN. Finally, in order to fully exert ATⅢ's antiinflammatory effects and regulation of renal microcirculatory haemodynamics, the dose of ATⅢ should be reconsidered and redefined instead of the dose used in sepsis or DIC if ATⅢ is applied for protecting against CIN.
In this study, we also revealed that baseline serum creatinine was an independent risk factor for CIN, which was highly supported by other studies [2, [54] [55] [56] [57] . The CIN Consensus Working Panel stated that the risk of CIN was increased when the baseline SCr is ≥114.9μmol/l in men and ≥88.4μmol/l in women [55] . Hence, we should pay more attention to patients with high baseline SCr and special precautions should be taken in these individuals.
Several limitations still exist in our study. Firstly, the number of enrolled patients is relative small, especially of the ones with low ATⅢ activities. Therefore, a retrospective analysis with a larger population is needed to reveal the clinical value of initial ATⅢ in CIN more accurately. Secondly, the current study didn't investigate the association between initial ATⅢ activities and short-term or long-term prognostic implications of CIN, including in-hospital mortality, 1 and 5-year mortality, chronic kidney diseases and requiring dialysis [58] . Further follow-up studies should be carried on to reveal the predictive value of ATⅢ in long term outcome of CIN.
Conclusions
Patients with low ATⅢ activity presented a higher risk of developing CIN after CAG. The initial ATⅢ activity was an independent predictor for CIN. Hence, it would be clinically valuable to pay more attention to patients with low ATⅢ activity before contrast media administration as well as take precautions to prevent or alleviate the development of CIN in these patients.
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